Creative Medical Technology Holdings, Inc. (CELZ) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 29, 2022, reports a material definitive agreement entered into by Creative Medical Technology Holdings, Inc. The transaction was completed on May 3, 2022, involving a private placement of equity securities to institutional investors.
Key Financial Metrics
- Gross Proceeds: Approximately $17,000,000.
- Offering Price: $2.25 per share of Common Stock/Pre-Funded Warrant and related Common Warrant.
- Placement Agent Fee: $1,360,000 paid to Roth Capital Partners.
- Placement Agent Warrant: 1,133,333 shares issued to Roth Capital Partners.
Material Changes and Transaction Details
The Company sold the following securities pursuant to a Securities Purchase Agreement:
- Common Stock: 2,991,669 shares.
- Pre-Funded Warrants: Warrants to purchase 4,563,887 shares (Exercise price: $0.0001; No expiration).
- Common Warrants: Warrants to purchase 15,111,112 shares (Exercise price: $2.00; Five-year term).
The transaction was conducted under Section 4(a)(2) of the Securities Act and Rule 506(b). The filing text does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period, as this report focuses solely on the capital raise event.
Outlook, Management Commentary, and Risks
Registration Rights: The Company agreed to file a registration statement to register the resale of the issued shares and underlying warrant shares.
Lock-Up Agreements: Directors and officers agreed not to sell their securities for 90 days following the earliest of the effective date of the Registration Statement or the date all offering securities can be sold under Rule 144 without volume limitations.
Risks: The filing notes that the information is qualified by reference to the actual terms of the Purchase Agreement and related exhibits. No specific operational risks or contingencies beyond the standard terms of the offering are detailed in the text provided.
Key Facts for Investor Verification
- Verify the net proceeds after deducting the $1,360,000 placement fee and other transaction costs.
- Confirm the dilution impact of the 2,991,669 shares sold plus the 19,675,000 shares underlying the warrants.
- Review the Registration Rights Agreement (Exhibit 10.2) for specific timelines regarding the resale registration.
- Check the Company's latest 10-K or 10-Q for current liquidity status and debt obligations, as this 8-K does not contain balance sheet data.